ArticlePharmacogenomics and personalized medicine2013
Delivering pharmacogenetic testing in a primary care setting.
Article in Pharmacogenomics and personalized medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.Pharmacogenomics · 2017Trial
- Integrating genomic medicine into primary care: a precision health model from Riyadh, Saudi Arabia.Family medicine and community health · 2026Article
- Readiness to Accept Genetic Testing for Personalized Medicine: Survey Findings on the Role of Socio-Demographic Characteristics, Health Vulnerabilities, Perceived Genetic Risk and Personality Factors.Journal of personalized medicine · 2022Article
- Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models.Pharmacogenomics · 2021Review
- The Extent and Impact of Variation in ADME Genes in Sub-Saharan African Populations.Frontiers in pharmacology · 2021Article
- Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic.Journal of clinical medicine · 2020Article
- Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective.Frontiers in genetics · 2020Article
- A stepwise approach to implementing pharmacogenetic testing in the primary care setting.Pharmacogenomics · 2019Article
- The importance of buprenorphine research in the opioid crisis.Molecular psychiatry · 2019Article
- Developing Pharmacogenomic Reports: Insights from Patients and Clinicians.Clinical and translational science · 2018Article
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
- Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry?Focus (American Psychiatric Publishing) · 2017Review
- Genetic Testing for Opioid Pain Management: A Primer.Pain and therapy · 2017Article
- Integrating pharmacogenetic testing into primary care.Expert review of precision medicine and drug development · 2017Article
- A review of consent practices and perspectives for pharmacogenetic testing.Pharmacogenomics · 2016Review
- A Use Case to Support Precision Medicine for Frequently Hospitalized Older Adults with Polypharmacy.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2016Article
- Potential utility of precision medicine for older adults with polypharmacy: a case series study.Pharmacogenomics and personalized medicine · 2016Article
- An inter-professional approach to personalized medicine education: one institution's experience.Personalized medicine · 2015Article
- Ethical perspectives on translational pharmacogenetic research involving children.Paediatric drugs · 2015Review
- Nurses' communication of pharmacogenetic test results as part of discharge care.Pharmacogenomics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pharmacogenetic testing refers to a type of genetic test to predict a patient's likelihood to experience an adverse event or not respond to a given drug. Despite revision to several labels of commonly prescribed drugs regarding the impact of genetic variation, the use of this testing has been limited in many settings due to a number of factors. In the primary care setting, the limited office time as well as the limited knowledge and experience of primary care practitioners have likely attributed to the slow uptake of pharmacogenetic testing. This paper provides talking points for primary care physicians to discuss with patients when pharmacogenetic testing is warranted. As patients and physicians become more familiar and accepting of pharmacogenetic testing, it is anticipated that discussion time will be comparable to that of other clinical tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.